Dongcheng Pharmaceutical (002675.SZ): Fluorine [18F] sirtide peptide injection completes Phase III clinical trial.

Beijing Business News app reported that Dongcheng Pharmaceutical (002675.SZ) announced that its controlling subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. (referred to as "Lanna Cheng") is developing a fluorine [18F] Siruipeptide injection, a targeted radioactive diagnostic drug for PSMA in prostate cancer patients with PSMA-positive lesions. It is suitable for Positron Emission Tomography (PET) imaging of prostate cancer patients who are planning to receive initial curative treatment and suspect the presence of metastatic lesions, as well as prostate cancer patients with elevated serum prostate-specific antigen (PSA) levels who suspect biochemical recurrence.